Protein Biologics are class of Biopharmaceuticals that are composed of protein molecules. Biologics, in general, can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. Other Biologics include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy (including stem cells).
Biosimilars are biologics that are highly similar to the reference biological product with no clinically meaningful differences in terms of safety profile, purity, and potency. Protein Biologics and Biosimilars include Modified human proteins, Monoclonal antibodies, Vaccines, Growth factors and cytokines, Hormones, and other protein Blood products.
Global biopharmaceuticals market was valued at USD 237250.8 million in 2018, and is estimated to be valued at USD 388997.3 million in 2024, witnessing a CAGR of 8.59%. according to a market research company Mordor Intelligence. According to the report it is also evident that almost Proteins in one way or another has acquired every drug manufacturer’s attention, Majorly they are Antibodies, Vaccines and recombinant proteins.